AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease
AVROBIO,Inc. | September 22, 2017
AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Pompe disease. This pre-clinical program becomes AVROBIO’s third gene therapy for Lysosomal Storage Disorders (LSDs), following on the heels of the Company’s Phase 1 Fabry program and pre-Phase 1/2 Gaucher program.